Literature DB >> 17051250

Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.

S Sabbioni1, E Callegari, M Manservigi, R Argnani, A Corallini, M Negrini, R Manservigi.   

Abstract

Silencing of gene expression by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis of mammalian cells. The use of DNA-based plasmid vectors to achieve transient and stable expression of siRNA has been developed to avoid the problems of double-stranded oligonucleotides transfection. These vectors direct the transcription of small hairpin RNAs (shRNAs) from a polymerase-III (H1 or U6)-RNA gene promoter. However, numerous disadvantages remain, including low transfection efficiency and difficulty in transfecting primary cells. To overcome some of these problems, the use of viral vectors for siRNA delivery has been described. Retroviral, adenoviral, adeno-associated and herpes viral shRNAs delivery systems have been successfully used to silence genes, in vitro and in vivo. The use of a herpes simplex virus type 1 (HSV-1)-based amplicon vector for siRNA delivery into mammalian cells, using human polyomavirus BK (BKV)-transformed cells as a model system is described. The results demonstrate the ability of amplicon vectors to inhibit the expression of BKV T-Ag and tumorigenicity of BKV-transformed cells. We show that the use of the amplicon vector is highly efficient for the delivery of siRNA molecules. The unique ability of these vectors to deliver multiple copies of siRNA may provide a useful tool in the development of novel anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051250     DOI: 10.1038/sj.gt.3302878

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  6 in total

1.  Inhibition of human immunodeficiency virus replication by cell membrane-crossing oligomers.

Authors:  Wilfried Posch; Stefan Piper; Thomas Lindhorst; Birgit Werner; Adam Fletcher; Holger Bock; Cornelia Lass-Flörl; Heribert Stoiber; Doris Wilflingseder
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

2.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

3.  Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Authors:  Anna-Maria Anesti; Guy R Simpson; Toby Price; Hardev S Pandha; Robert S Coffin
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

4.  Porous silicon-graphene oxide core-shell nanoparticles for targeted delivery of siRNA to the injured brain.

Authors:  Jinmyoung Joo; Ester J Kwon; Jinyoung Kang; Matthew Skalak; Emily J Anglin; Aman P Mann; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Nanoscale Horiz       Date:  2016-06-14       Impact factor: 10.989

5.  Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus.

Authors:  Anna-Maria Anesti; Pieter J Peeters; Ines Royaux; Robert S Coffin
Journal:  Nucleic Acids Res       Date:  2008-06-25       Impact factor: 16.971

Review 6.  RNA interference technologies and therapeutics: from basic research to products.

Authors:  Marta López-Fraga; Tamara Martínez; Ana Jiménez
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.